DUBLIN--(BUSINESS WIRE)--
Research and Markets has announced the addition of the "Dermatomyositis - Pipeline Review, H2 2016" report to their offering.
Dermatomyositis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 2 respectively.
Dermatomyositis.
Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/7wx7lc/dermatomyositis

View source version on businesswire.com: http://www.businesswire.com/news/home/20161209005454/en/